COMP <GO>
PTGX vs TGTX // DIVIDEND YIELD & FCF PAYOUT SAFETY
Protagonist Therapeutics Inc. (NASDAQ) VS. TG Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PTGX 3
— TGTX 7
■ METRIC PARITY
LAST: $139.37 (-3.78%) • MKT CAP: $9.02B
dividend-safety
0.00%
LAST: $59.95 (-2.01%) • MKT CAP: $9.18B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. TGTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | TGTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | 12.00% | -28.70 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 73.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | -0.28% | +0.88 | PTGX | /fcf-yield <GO> |
| Operating Margin | -6.00% | 20.00% | -26.00 | TGTX | /operating-margins <GO> |
| Net Profit Margin | -5.00% | 68.00% | -73.00 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 87.30% | -87.30 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 12.92 | +13.08 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.3 | 60.3 | -14.00 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.87 | +0.12 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 16.7x | +14.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.02B | $9.18B | -$158.1M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | TGTX REV | PTGX GROSS % | TGTX GROSS % | PTGX FCF | TGTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $442.8M | $616.3M | — | 83.7% | $56.1M | -$25.0M |
| FY 2024 | $708.0M | $329.0M | — | 88.3% | $182.8M | -$40.6M |
| FY 2023 | $262.2M | $233.7M | — | — | -$70.2M | -$41.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
TGTX // BETA 0.87